Kenvue Inc. $KVUE Stock Holdings Increased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its holdings in Kenvue Inc. (NYSE:KVUE) by 28.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,814 shares of the company’s stock after purchasing an additional 35,263 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Kenvue were worth $2,774,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of KVUE. Norges Bank purchased a new stake in shares of Kenvue during the fourth quarter valued at $756,862,000. Van ECK Associates Corp lifted its holdings in shares of Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after purchasing an additional 9,240,434 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Kenvue by 22.4% during the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after purchasing an additional 6,781,640 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Kenvue by 156.2% during the fourth quarter. Bessemer Group Inc. now owns 8,491,343 shares of the company’s stock valued at $146,475,000 after purchasing an additional 5,177,404 shares during the last quarter. Finally, Mondrian Investment Partners LTD purchased a new stake in shares of Kenvue during the third quarter valued at $79,269,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 2.0%

Shares of Kenvue stock opened at $17.91 on Wednesday. The stock has a 50-day moving average price of $17.38 and a 200 day moving average price of $17.51. The company has a market cap of $34.38 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.33 and a beta of 0.54. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.24 EPS. As a group, analysts expect that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is presently 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.59% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on KVUE shares. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group reduced their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Barclays reduced their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Finally, Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.